H.C. Wainwright analyst Matthew Caufield moved its rating on Aldeyra Therapeutics to Under Review after the company received late-cycle review minutes from the FDA related to the application for reproxalap in the topical treatment of signs and symptoms of dry eye disease.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALDX:
- Aldeyra price target lowered to $11 from $30 at Laidlaw
- Aldeyra says FDA noted substantive review issues related to NDA for reproxalap
- Aldeyra downgraded to Perform from Outperform at Oppenheimer (earlier)
- Aldeyra trading resumes
- Aldeyra trading halted, volatility trading pause
Questions or Comments about the article? Write to editor@tipranks.com